Skip to main content
. 2018 Mar 7;65(5):578–583. doi: 10.1111/zph.12459

Table 1.

Demographic and clinical characteristics of staff persons, and results of serological surveillance

ID Sex, age, country of birth Smallpox vaccination Role in the farm Comorbidities Exposure to diseased monkeys Symptoms IFA virus target IgGa on Jan. 22, 2015 IgMa on Jan. 22, 2015 IgGa6 weeks later IgMa6 weeks later IgGa 12 weeks later IgMa 12 weeks later
1 M, 69, Italy Yes Coordinator No Yes (Direct assistance) No VL 1:80 <1:20 1:80 <1:20
OPV Abatino 1:80 <1:20 1:40 <1:20
2 M, 35, Italy No Veterinary No Yes (Direct assistance including intubation) Fever, general malaise, asthenia VL <1:40 <1:20 <1:40 <1:20
OPV Abatino <1:40 <1:20 <1:40 <1:20
3 M, 34, Albania Yes Maintenance staff No No No VL Weak positive <1:20 Weak positive <1:20
OPV Abatino 1:20 <1:20 1:20 <1:20
4 F, 37, Italy No Researcher No Yes (Direct assistance, removal of dead bodies) Fever, sore throat VL <1:40 <1:20 <1:40 <1:20
OPV Abatino <1:40 <1:20 <1:40 <1:20
5 F, 37, Italy No Researcher No No No VL <1:40 <1:20 <1:40 <1:20
OPV Abatino <1:40 <1:20 <1:40 <1:20
6 M, 38, Italy No Researcher Thyroidectomy Yes (Direct assistance, removal of dead bodies) No VL 1:20 <1:20 1:160 1:20 1:320 1:40
OPV Abatino 1:20 <1:20 1:320 1:40 1:640 1:40
7 F, 61, Albania Yes Maintenance staff Hypertension No No VL Weak positive <1:20 1:40 <1:20
OPV Abatino 1:20 <1:20 1:20 <1:20
8 F, 27, Italy No Researcher No No No VL <1:20 <1:20 <1:40 <1:20
OPV Abatino <1:20 <1:20 <1:40 <1:20
9 F, 29, France No Researcher No No No VL <1:20 <1:20 ND ND
OPV Abatino <1:20 <1:20
10 F, 38, Italy No Maintenance staff No No No VL <1:40 <1:20 <1:40 <1:20
OPV Abatino <1:40 <1:20 <1:40 <1:20
11 F, 67, Italy Yes Assistant Rheumatoid arthritis No No VL 1:80 <1:20 1:80 <1:20
OPV Abatino 1:80 <1:20 1:80 <1:20

ND, not done.

The IFA titre was established as the last serum dilution showing appreciable immunofluorescent staining.

a

The antibody titre was determined by IFA against LV and OPV Abatino.

This article is being made freely available through PubMed Central as part of the COVID-19 public health emergency response. It can be used for unrestricted research re-use and analysis in any form or by any means with acknowledgement of the original source, for the duration of the public health emergency.